Kate Sheridan
STAT
New York, NY, United States
Contact Kate
Discover and connect with journalists and influencers around the world, save time on email research, monitor the news, and more.
| Recent: |
|
| Past: |
|
Past articles by Kate:
People hate drug ads on TV. Here’s what they complain about most
We looked at the complaints people lodge with the FCC about prescription drug ads. Most focused on one of four issues. → Read More
FDA approves first microbiome drug from Ferring Pharmaceuticals
Rebyota is designed to restore balance in the digestive system by introducing good bacteria taken from donor stool samples. → Read More
Boom and bust: Whose biotech VC assets have grown and shrunk the most?
STAT analyzed yearly financial records from more than four dozen biotech investment firms that laid out their assets to determine which have seen the most growth over time. → Read More
Documents detail how pharmacy giants Walgreens, CVS, and Walmart failed patients in the opioid epidemic
Retail pharmacies shared more of the blame for the opioid crisis than previously reported — through willful blindness, weak controls, resistance from executives to improve monitoring, and in some cases, ineptitude. → Read More
Harassment prompts children’s hospitals to strip websites, threatening access to gender-affirming care
Children’s hospitals, facing harassment online, are stripping their websites of information about gender-affirming care. Doctors and advocates are concerned the changes will make it harder for patients to get care they need. → Read More
U.S. life expectancy drops sharply, the second consecutive decline
Americans born in 2021 can expect to live for just 76.1 years — the lowest life expectancy has been since 1996, according to a new analysis. It's the biggest two-year decline in almost 100 years. → Read More
OrbiMed tumbles from the top of STAT’s biotech venture capital performance ranking
For the first time, OrbiMed fell out of the top 10 in STAT’s biotech venture capital performance ranking. → Read More
Health care's high rollers: As the pandemic raged, CEOs' earnings surged
Special Report: Health care’s top executives are cushioned more than ever by the rising fortunes of their stock ownership. → Read More
Homeless and incarcerated people in Minnesota struggled to access Covid vaccines
Homeless and incarcerated people had significantly lower Covid vaccination rates than others in Minnesota, according to a new study. → Read More
What makes a biotech a biotech?
Historically, experts distinguished between biotech and pharma companies based on how a therapeutic was made. But the line’s gotten fuzzy, making it hard to measure things like how many companies exist or how many people the industry employs. → Read More
Some newly public biotech companies are trading below cash. Is it as bad as it looks?
One in four biotechs that went public in 2020 are trading below cash, according to a new STAT analysis. Is it as bad as it looks? → Read More
3 biotech trends to watch in 2022
STAT looks at 3 forces that shaped the financial landscape for biotech companies in 2021 — and why they will drive the markets in 2022. → Read More
Biotech investor Eli Casdin on biotech’s bad December
Biotech has always been perceived as “either a bubble or a disaster," biotech investor Eli Casdin said at a recent STAT event in New York. → Read More
Alnylam’s longtime CEO to depart, new leader named
John Maraganore, who has been the CEO of Alnylam for nearly 19 years, is stepping down on Dec. 31. Yvonne Greenstreet will be the next CEO. → Read More
Licensing biotech breakthroughs is a mess. Can it be fixed?
Tech transfer — the process of licensing scientific discoveries — is a contentious, painful slog. Can it be fixed? → Read More
What's up with tranched deals in biotech?
Tranche is a French word meaning slice and that's pretty much what it means in the language of venture capital as well. → Read More
Vedanta touts positive new data for its C. diff microbiome therapeutic
Vedanta revealed positive new data for its C. difficile microbiome therapeutic. But is it too late an entrant into the field? → Read More
In another sign of RNA’s growing popularity, Replicate is relaunching
The California startup Replicate is putting a new spin on a now-household idea: using RNA as the foundation of a new therapy. → Read More
Flagship, Orbimed, ARCH top list of high-performing biotech VC firms
A Flagship Pioneering fund had the highest multiple of any in a new STAT report that looks at returns for 17 biotech venture capital firms. → Read More
Even as it breaks biotech’s unwritten rules, Amylyx is raising big money
If you want to raise big money in biotech, there are a few unwritten rules. Amylyx is breaking all of them — and still bringing in investors. → Read More